## Claims

1. Use of neratinib and capecitabine in the manufacture of a medicament for treating a neoplasm, wherein the medicament is manufactured for administration of neratinib in an amount of at least 40 mg per day.

2. The use according to claim 1, wherein the neoplasm is a breast cancer.

3. The use according to claim 2, wherein the breast cancer is selected from an Erb-2 positive metastatic breast cancer and a locally advanced breast cancer.

4. The use according to claim 1, wherein the neoplasm is an Erb-2 positive solid tumor.

5. The use according to claim 1, wherein the medicament is manufactured for administering one or both of neratinib and capecitabine in a subtherapeutically effective amount.

6. The use according to claim 1, wherein the medicament is manufactured for oral administration of neratinib and capecitabine.

7. The use according to claim 1, wherein the medicament is manufactured for administering neratinib and capecitabine concurrently, sequentially, or simultaneously.

8. The use according to claim 1, wherein the medicament is manufactured for administering neratinib in a unit dose.

9. The use according to claim 1, wherein the medicament is manufactured for administering capecitabine in a unit dose.

10. The use according to claim 1, wherein the medicament is manufactured for administering capecitabine in an amount of 1250 mg to 3000 mg daily.

11. The use according to claim 1, wherein the medicament is manufactured for administering capecitabine at least once over a period of 21 days.

12. The use according to claim 11, wherein the medicament is manufactured for continuing administration of capecitabine for 3 to 6 cycles.

13. The use according to claim 1, wherein the medicament is manufactured for administering neratinib in an amount of at least 120 mg per day.

14. The use according to claim 1, wherein the medicament is manufactured for administering neratinib in an amount of at least 240 mg per day.

15. The use according to claim 1, wherein the medicament is manufactured for administering neratinib daily.

16. The use according to claim 1, wherein the medicament is manufactured for administering neratinib at least once daily.

17. The use according to claim 1, wherein the medicament is manufactured for administering neratinib for at least 2 continuous weeks.

18. The use according to claim 1, wherein the medicament is manufactured for administering neratinib before capecitabine.

19. The use according to claim 1, wherein the medicament is manufactured for administering neratinib after capecitabine.

20. The use according to claim 1, wherein the medicament is manufactured for administering neratinib and capecitabine simultaneously.

21. The use according to claim 1, wherein the medicament is manufactured for discontinuing administration of capecitabine after 24 weeks.

22. Use of neratinib and capecitabine in the manufacture of a medicament for treating a breast cancer, wherein one treatment cycle comprises 21 days and wherein the medicament is manufactured for administering neratinib orally at least one unit dose daily starting on day 1 of said cycle and capecitabine orally at least one unit dose on days 1 to 14 of said cycle.

23. A pharmaceutical composition consisting of capecitabine, neratinib, and at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential delivery for treating a neoplasm in a mammal.

24. A pharmaceutical pack for treating a neoplasm in one individual mammal, said pharmaceutical pack consisting of:

(a) at least one unit dose of capecitabine; and

(b) at least one unit dose of neratinib.

25. Use of neratinib and capecitabine in the manufacture of a medicament for treating a neoplasm, wherein the medicament is manufactured for administering neratinib in a dose range of 20 to 240 mg per day.

## CLAIMS

1. An invention not claimed in any divisional application.